The companies have partnered to jointly offer products and services for cancer specimen research and clinical data analysis.
As part of the deal, Helomics will promote MDNA's Prostate Core Mitomic Test and its liquid biopsy Prostate Mitomic Test in select US markets.
The firm will provide product enhancement and clinical lab services, including comprehensive tumor profiling using proprietary cell-based products and services.
The firms have eliminated several terms of their original deal and have cross-licensed IP to allow Med BioGene to license Gene FX Lung to other firms.
The company also intends to eventually offer the two additions, which expand the granularity of its live-cell analysis platform, for clinical use.
Helomics will provide its technology to the GENE Consortium, formed to support the UK's 100,000 Genomes Project.
Helomics' tumor profiling products and services, including ChemoFx, will be available to more than 700,000 Prime Health Services providers.
Formerly called Precision Therapeutics, the company recently received a $60 million investment and ushered in new management.
NEW YORK (GenomeWeb) – Precision Therapeutics today announced a $60 million investment and a new name, Helomics.
NEW YORK (GenomeWeb) – Med BioGene today announced that it is ready to initiate proceedings against its commercial partner Precision Therapeutics to enforce a C$1 million (US$920,000) milestone payment due to Med BioGene.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.